Oritavancin diphosphate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for oritavancin diphosphate and what is the scope of freedom to operate?
Oritavancin diphosphate
is the generic ingredient in two branded drugs marketed by Melinta Therap and is included in two NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Oritavancin diphosphate has thirty-nine patent family members in seventeen countries.
One supplier is listed for this compound.
Summary for oritavancin diphosphate
International Patents: | 39 |
US Patents: | 3 |
Tradenames: | 2 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 27 |
Clinical Trials: | 4 |
Patent Applications: | 54 |
What excipients (inactive ingredients) are in oritavancin diphosphate? | oritavancin diphosphate excipients list |
DailyMed Link: | oritavancin diphosphate at DailyMed |
Recent Clinical Trials for oritavancin diphosphate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Melinta Therapeutics, Inc. | Phase 2 |
The Medicines Company | Phase 1 |
Pharmacology for oritavancin diphosphate
Drug Class | Lipoglycopeptide Antibacterial |
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C9 Inhibitors Cytochrome P450 2D6 Inducers Cytochrome P450 3A4 Inducers |
Anatomical Therapeutic Chemical (ATC) Classes for oritavancin diphosphate
US Patents and Regulatory Information for oritavancin diphosphate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Melinta Therap | KIMYRSA | oritavancin diphosphate | POWDER;INTRAVENOUS | 214155-001 | Mar 12, 2021 | RX | Yes | Yes | 9,682,061 | ⤷ Subscribe | ⤷ Subscribe | ||||
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | RX | Yes | Yes | 8,420,592 | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for oritavancin diphosphate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | 5,840,684 | ⤷ Subscribe |
Melinta Therap | ORBACTIV | oritavancin diphosphate | POWDER;INTRAVENOUS | 206334-001 | Aug 6, 2014 | 5,998,581 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for oritavancin diphosphate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | E027373 | ⤷ Subscribe | |
Spain | 2570401 | ⤷ Subscribe | |
Norway | 2016019 | ⤷ Subscribe | |
European Patent Office | 3006038 | METHODES DE TRAITEMENT UTILISANT DES DOSES UNIQUES D'ORITAVANCINE (METHODS OF TREATMENT USING SINGLE DOSES OF ORITAVANCIN) | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for oritavancin diphosphate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2337575 | 122016000075 | Germany | ⤷ Subscribe | PRODUCT NAME: ORITAVANCIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/989 20150319 |
2337575 | 1690041-7 | Sweden | ⤷ Subscribe | PRODUCT NAME: ORITAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/15/989 20150323 |
2337575 | 300834 | Netherlands | ⤷ Subscribe | PRODUCT NAME: ORITAVANCIN; REGISTRATION NO/DATE: EU/1/15/989 20150323 |
2337575 | 16C0039 | France | ⤷ Subscribe | PRODUCT NAME: ORITAVANCINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES,TELS QUE LES SELS DIPHOSPHATES; REGISTRATION NO/DATE: EU/1/15/989 20150323 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Oritavancin diphosphate Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.